Details for Patent: 12,458,632

Which drugs does patent 12,458,632 protect, and when does it expire?

Patent 12,458,632 protects UBRELVY and is included in one NDA.

This patent has forty-one patent family members in thirteen countries.

Summary for Patent: 12,458,632

Title:	Treatment of migraine
Abstract:	The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Inventor(s):	Mary Ann Johnson, Leonardo R. Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
Assignee:	Merck Sharp and Dohme LLC
Application Number:	US19/042,453
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 12,458,632

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	UBRELVY	ubrogepant	TABLET;ORAL	211765-001	Dec 23, 2019		RX	Yes	No	12,458,632		Y
Abbvie	UBRELVY	ubrogepant	TABLET;ORAL	211765-002	Dec 23, 2019		RX	Yes	Yes	12,458,632		Y

International Family Members for US Patent 12,458,632

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015214502
Australia	2019226239
Australia	2021245229
Australia	2021409718
Australia	2023258317